Dehydrodiisoeugenol (DEH) is a representative and major benzofuran-type neolignan found in Myristica fragrans Houtt, possessing antibacterial, anti-inflammatory, anticancer, and antioxidant properties. Dehydrodiisoeugenol inhibits the proliferation of colorectal cancer cells and induces apoptosis, autophagy, endoplasmic reticulum stress and cell cycle arrest. Dehydrodiisoeugenol is commonly used in the research related to colorectal cancer, inflammatory diseases and ulcerative colitis[1][2][3].
In vitro, treatment with Dehydrodiisoeugenol (2.5, 5 and 10µM) for 24h inhibited the activation of the NF-κB and MAPK signaling pathways and dose-dependently suppressed the expression of inflammatory mediators, including NO, iNOS, COX-2, PGE₂, IL-1β, IL-6, and TNF-α in the LPS/IFNγ-induced RAW264.7 ulcerative colitis (UC) model[1]. Treatment with Dehydrodiisoeugenol (40, 80, and 100µM) for 24h significantly inhibited the viability of HCT116 and HT29 cells[1]. Treatment with Dehydrodiisoeugenol at 40µM for 24h induced apoptosis in HCT116 cells, suppressing Bcl-2 expression while upregulating Bax expression[1].
In vivo, oral administration of Dehydrodiisoeugenol at 40mg/kg for 20 days significantly inhibited tumor growth in BALB/c nude mice transplanted with HCT116 cells[1]. Oral gavage administration of Dehydrodiisoeugenol at 20mg/kg/d for 8 days significantly improved rectal bleeding in DSS-induced mice[1].
References:
[1] Yi F, Chen N, Zhao M, et al. Dehydrodiisoeugenol targets NOD2 exerting dual effects against colitis and colorectal cancer: a double-edged sword. Mol Med. 2025;31(1):221.
[2] Li C, Zhang K, Pan G, et al. Dehydrodiisoeugenol inhibits colorectal cancer growth by endoplasmic reticulum stress-induced autophagic pathways. J Exp Clin Cancer Res. 2021;40(1):125.
[3] Murakami Y, Shoji M, Hirata A, Tanaka S, Yokoe I, Fujisawa S. Dehydrodiisoeugenol, an isoeugenol dimer, inhibits lipopolysaccharide-stimulated nuclear factor kappa B activation and cyclooxygenase-2 expression in macrophages. Arch Biochem Biophys. 2005;434(2):326-332.
Dehydrodiisoeugenol（DEH）是香豆蔻中具有代表性的主要苯并呋喃型新木质素，具有抗菌、抗炎、抗癌、抗氧化等特性。Dehydrodiisoeugenol能抑制结直肠癌细胞增殖，诱导凋亡、自噬、内质网应激和细胞周期阻滞。Dehydrodiisoeugenol常用于结直肠癌、炎症性疾病和溃疡性结肠炎的相关研究[1][2][3]。
体内实验中，在LPS/IFN-γ诱导的RAW264.7溃疡性结肠炎（UC）模型中，用2.5、5和10µM Dehydrodiisoeugenol处理24小时，可抑制NF-κB和MAPK信号通路的激活，并以剂量依赖性方式抑制NO、iNOS、COX-2、PGE₂、IL-1β、IL-6和TNF-α等炎症因子的表达[1]。用Dehydrodiisoeugenol（40、80和100 µM）处理24小时可显著抑制HCT116和HT29细胞的活力[1]。以40µM的DEH处理HCT116细胞24小时可诱导细胞凋亡，抑制Bcl-2的表达，同时上调Bax的表达[1]。
体外实验中，以40mg/kg 剂量口服给予Dehydrodiisoeugenol20天，可显著抑制移植了HCT116细胞的BALB/c裸鼠中的肿瘤生长。以20mg/kg/d的Dehydrodiisoeugenol口服灌胃给药8天，可显著改善DSS诱导小鼠的直肠出血情况[1]。